FDA Retires Another COVID Test From Its Emergency-Use Era
Published Date: 6/26/2025
Notice
Summary
The FDA has officially ended the emergency use approval for Cepheid’s Xpert Xpress COVID-19 test as of May 28, 2025, because the company asked for it. This means the test can no longer be used under emergency rules, but it doesn’t affect other COVID-19 tests. Labs and healthcare providers should plan accordingly, but there’s no direct cost impact for the public.
Analyzed Economic Effects
1 provisions identified: 0 benefits, 0 costs, 1 mixed.
Cepheid Xpert Xpress EUA Revoked
The FDA revoked the Emergency Use Authorization (EUA) for Cepheid’s Xpert Xpress SARS-CoV-2 test effective May 28, 2025, so that specific test can no longer be used under EUA. Cepheid told FDA that all its U.S. customers transitioned to the Xpert Xpress SARS-CoV-2 plus product (authorized under EUA220187), and FDA says labs and healthcare providers should plan accordingly. FDA also stated the revocation does not affect other COVID-19 tests and has no direct cost impact for the public.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-20848, Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods
The FDA is changing food rules to allow salt substitutes in many standardized foods, helping companies make lower-sodium options. This move aims to cut heart disease risks by reducing sodium without changing how foods basically taste or look. The new rule kicks in December 14, 2026, and food makers have until November 12, 2026, to raise any concerns, with no big costs expected.
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
Previous / Next Documents
Previous: 2025-11820, Public Water System Supervision Program Revision for New York; Notice of Approval and Opportunity for Public Comment and Public Hearing
New York has updated its drinking water rules to better control harmful chemicals from disinfectants. The EPA says these new rules meet federal standards and is ready to approve them. People can share their thoughts or ask for a public hearing by July 28, 2025, but no big costs or changes are expected right now.
Next: 2025-11823, Meeting of the Interagency Task Force on Veterans Small Business Development
The SBA is hosting a virtual meeting on July 15, 2025, to boost support for veteran-owned small businesses. This meeting will focus on improving access to funding, business growth, and federal contracts for veterans. Veterans and small business owners should RSVP by July 8 to join or share their ideas and help shape future programs.